Gendx Tissue Typing
Closed Special Notice Posted
- Solicitation number
- 36C26325Q1006
- Agency
- Veterans Integrated Service Network 23 Veterans Health Administration, Department of Veterans Affairs
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Place of performance
- Iowa City, Iowa 52246, United States
- Points of contact
-
- Emanuel Nevarez emanuel.nevarez@va.gov (320) 255-6354
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 23 has published a Notice of Intent for a sole source contract award to GenDx Products LLC for Next Generation Sequencing (NGS) kits to support the Iowa City VA Health Care System. This special notice, posted on July 30, 2025 with responses due by August 6, 2025, is issued under Federal Acquisition Regulation 5.101(a)(1) to inform the market of the proposed contract action. The procurement is justified under 41 U.S.C. 3304(a)(1) and FAR 6.302-1 as a sole source acquisition, with market research indicating that GenDx Products LLC is the only company capable of providing the required NGS kits. The contract falls under NAICS code 325413 for In Vitro Diagnostic Substance Manufacturing and PSC code 6550 for diagnostic substances and test kits. This notice serves to announce the government's intent to proceed with a non-competitive award to the identified contractor.
The primary purpose of this notice is to provide transparency regarding the VA's planned sole source procurement while offering an opportunity for other potential contractors to demonstrate their capabilities. Interested vendors have until August 6, 2025 to submit capability statements and supporting documentation to Contracting Specialist Emanuel Nevarez via email, using the subject line "36C26325Q1006 BD GENDX Tissue Typing." To be considered as an alternative source, contractors must provide documentation from GenDx Products LLC proving they are an authorized reseller, dealer, or third party capable of providing the required services. The contract will be an Indefinite Delivery-Indefinite Quantity firm fixed-price agreement covering three ordering periods from October 2025 through September 2028, specifically for NGS reagent kits used in human leukocyte antigen allele identification compatible with Illumina MiSeq instruments. The VA will review all submitted capability statements solely to determine whether the procurement should be conducted on a competitive basis rather than as the planned sole source award.
Notice text
This is a Notice of Intent published in accordance with Federal Acquisition Regulation (FAR) 5.101(a)(1) requiring the dissemination of information regarding proposed contract actions. This Notice of Intent is for a proposed award of a sole source firm fixed price contract to the following contractor in support of needed Next Generation Sequencing (NGS) kits to support the Iowa City VA Health Care System.
GENDX PRODUCTS LLC
SAM UEI: JFZKARM2NL52
15222 Avenue Of Science STE A
San Diego, California
92128-3422, United States
This is done under authority of 41 U.S.C. 3304(a)(1), as implemented by FAR 6.302-1: Only one source and no other supplies or services will satisfy agency requirements.
This is not a request for competitive quotes.
Market research revealed that GENDX PRODUCTS LLCis the sole company that is able to provide support for the needed Next Generation Sequencing (NGS) kits to support the Iowa City VA Health Care System.
The North American Industry Classification System (NAICS) code for this service is 325413 (In Vitro Diagnostic Substance Manufacturing) and the Product Service Code (PSC) is 6550 (In Vitro Diagnostic Substances, Reagents, Test Kits and Sets).
While this synopsis does not constitute a solicitation, interested vendors may identify their interest and capability to satisfy the requirement, including documentation from the proprietary rights holder GENDX PRODUCTS LLCthat such contractor could provide this service as an authorized reseller, authorized dealer or third party.
All responsible sources may submit a capability statement, which shall be considered by the agency by e-mailing such statement and supporting documentation to Emanuel Nevarez, Contracting Specialist emanuel.nevarez@va.gov. No phone calls please. Please indicate “36C26325Q1006 BD GENDX Tissue Typing” in subject line of e-mail.
Such documentation will be reviewed solely for the purpose of determining whether or not to conduct the procurement on a competitive basis. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government under authorities cited above.
See Attached Statement of Work (SOW)
Attachments
| File | Type | Posted |
|---|---|---|
| GenDx Reagents SOW FY26.docx | DOCX document |
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity